Tom Hearn

Tom Hearn

Auto-generated profile, based on publicly available information

Tom Hearn

Swansea University Medical School Singleton Park, Swansea, United Kingdom

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2002 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
THTom Hearn
Tom Hearn
GRGlenn L. Renforth
Glenn L. Renforth
CSCosma Spalluto
Cosma Spalluto
NHNeil A. Hanley
Neil A. Hanley
KHKaren Piper Hanley
Karen Piper Hanley
DWDavid I. Wilson
David I. Wilson

1 May 2005 in Diabetes
Verified
Journal Article
Closed access
PDF file
THTom Hearn
Tom Hearn
CSCosma Spalluto
Cosma Spalluto
VPVictoria J. Phillips
Victoria J. Phillips
GRGlenn L. Renforth
Glenn L. Renforth
NCNane Copin
Nane Copin
DWDavid I. Wilson
David I. Wilson
Alström syndrome is a rare autosomal recessive disorder caused by mutations in a novel gene of unknown function, ALMS1. Central features of Alström syndrome include obesity, insulin resistance, and type 2 diabetes, and therefore investigating ALMS1 function stands to offer new insights into the pathogenesis of these common conditions. To begin this process, we have analyzed the subcellular localization and tissue distribution of ALMS1 by immunofluorescence. We show that ALMS1 is widely expressed and localizes to centrosomes and to the base of cilia. Fibroblasts with disrupted ALMS1 assemble primary cilia and microtubule cytoskeletons that appear normal, suggesting that the Alström syndrome phenotype results from impaired function rather than abnormal development. Coupled with recent data on the complex phenotype of Bardet-Biedl syndrome, our findings imply an unexpected central role for basal body and centrosome dysfunction in the pathogenesis of obesity, insulin resistance, and type 2 diabetes. Unraveling the molecular mechanisms underlying the Alström syndrome phenotype will be important in the search for new therapeutic targets for these conditions.

11 October 2007 in Human Mutation
Verified
Journal Article
Closed access
PDF file
JMJan D. Marshall
Jan D. Marshall
EHElizabeth G. Hinman
Elizabeth G. Hinman
GCGayle B. Collin
Gayle B. Collin
SBSebastian Beck
Sebastian Beck
RCRita Cerqueira
Rita Cerqueira
JNJürgen Naggert
Jürgen Naggert
Alström syndrome is a monogenic recessive disorder featuring an array of clinical manifestations, with systemic fibrosis and multiple organ involvement, including retinal degeneration, hearing loss, childhood obesity, diabetes mellitus, dilated cardiomyopathy (DCM), urological dysfunction, and pulmonary, hepatic, and renal failure. We evaluated a large cohort of patients with Alström syndrome for mutations in the ALMS1 gene. In total, 79 disease‐causing variants were identified, of which 55 are novel mutations. The variants are primarily clustered in exons 8, 10, and 16, although we also identified novel mutations in exons 12 and 18. Most alleles were identified only once (45/79), but several were found recurrently. Founder effects are likely in families of English and Turkish descent. We also identified 66 SNPs and assessed the functional significance of these variants based on the conserved identity of the protein and the severity of the resulting amino acid substitution. A genotype–phenotype association study examining 18 phenotypic parameters in a subset of 58 patients found suggestive associations between disease‐causing variants in exon 16 and the onset of retinal degeneration before the age of 1 year (P = 0.02), the occurrence of urological dysfunction (P = 0.02), of DCM (P = 0.03), and of diabetes (P = 0.03). A significant association was found between alterations in exon 8 and absent, mild, or delayed renal disease (P = 0.0007). This data may have implications for the understanding of the molecular mechanisms of ALMS1 and provides the basis for further investigation of how alternative splicing of ALMS1 contributes to the severity of the disease. Hum Mutat 28(11),1114–1123, 2007. Published 2007 Wiley‐Liss, Inc.

12 November 2018 in Journal of Molecular Medicine
Verified
Journal Article
Open access
PDF file
THTom Hearn
Tom Hearn
Alström syndrome (AS) is characterised by metabolic deficits, retinal dystrophy, sensorineural hearing loss, dilated cardiomyopathy and multi-organ fibrosis. Elucidating the function of the mutated gene, ALMS1, is critical for the development of specific treatments and may uncover pathways relevant to a range of other disorders including common forms of obesity and type 2 diabetes. Interest in ALMS1 is heightened by the recent discovery of its involvement in neonatal cardiomyocyte cell cycle arrest, a process with potential relevance to regenerative medicine. ALMS1 encodes a ~ 0.5 megadalton protein that localises to the base of centrioles. Some studies have suggested a role for this protein in maintaining centriole-nucleated sensory organelles termed primary cilia, and AS is now considered to belong to the growing class of human genetic disorders linked to ciliary dysfunction (ciliopathies). However, mechanistic details are lacking, and recent studies have implicated ALMS1 in several processes including endosomal trafficking, actin organisation, maintenance of centrosome cohesion and transcription. In line with a more complex picture, multiple isoforms of the protein likely exist and non-centrosomal sites of localisation have been reported. This review outlines the evidence for both ciliary and extra-ciliary functions of ALMS1.

1 February 1999 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
MJMichael Jackson
Michael Jackson
MRM. Rocchi
M. Rocchi
GTG. Thompson
G. Thompson
THT. Hearn
T. Hearn
MCM. Crosier
M. Crosier
NAN. Archidiacono
N. Archidiacono
Little is known about sequence organization close to human centromeres, despite empirical and theoretical data which suggest that it may be unusual. Here we present maps which physically define large sequence duplications flanking the centromeric satellites of human chromosome 10, together with a fluorescence in situ hybridization (FISH) analysis of pericentromeric sequence stability. Our results indicate that the duplications on each chromosome arm are organized into two blocks of ∼250 and 150 kb separated by ∼300 kb of non-duplicated DNA. The larger proximal blocks, containing ZNF11A, ZNF33A and ZNF37A (10p11) and ZNF11B, ZNF33B and ZNF37B (10q11), are inverted. However, the smaller distal blocks, containing D10S141A (10p11) and D10S141B (10q11), are not. A primate FISH analysis indicates that these loci were duplicated before the divergence of orang-utans from other Great Apes, that a cytogenetically cryptic pericentric inversion may have been involved in the formation of the flanking duplications and that they have undergone further rearrangement in other primate species. More surprising is the fact that sequences across the entire pericentromeric region appear to have undergone unprecedented levels of duplication, transposition, inversion and either deletion or sequence divergence in all primate species analysed. Extrapolating our data to the whole genome suggests that a minimum of 50 Mb of DNA in centromere-proximal regions is subject to an elevated level of mechanistically diverse sequence rearrangements compared with the bulk of genomic DNA.

5 September 2003 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
SBS Brickwood
S Brickwood
DBDavid Bonthron
David Bonthron
LAL I Al-Gazali
L I Al-Gazali
KPK Piper
K Piper
THT Hearn
T Hearn
NHN A Hanley
N A Hanley
Primers were designed to amplify all EIF2AK3 exons and splice site sequences from genomic DNA (table 1). Sequences were amplified by 35 cycles of polymerase chain reaction (PCR) using a proof-reading DNA polymerase in 50 μl reactions and purified (Qiaquick, Qiagen, Crawley, Sussex, UK). Products were sequenced using the BigDye terminator cycle sequencing kit according to the manufacturer’s instructions (Perkin-Elmer, Foster City, California, USA) and an ABI 377 sequencer (Applied Biosystems, city, county, UK). Sequences were compared to the published EIF2AK3 gene by BLAST analysis (http://www.ncbi.nlm.nih.gov/BLAST/). For potential mutations, the PCR and sequencing was repeated to confirm the result. Restriction digest analysis was also used to confirm the mutation in case 2, where the G→A substitution destroyed an HphI site.